PERK-eif2α signalling plays an important role in T-cell exhaustion, the development and maintenance of MDSCs, and PD-L1 expression in tumour cells, suggesting that targeting PERK-eif2α signalling is a promising strategy for the treatment of cancers. This evidence concerns the gene EIF2AK3 and neoplasm.